2022 Continuous Glucose Monitoring Systems Market Report: A $4.43 Bn Market in 2021 - Global Forecast to 2027 - ResearchAndMarkets.com

The "Continuous Glucose Monitoring Systems Market Intelligence Report - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

The Global Continuous Glucose Monitoring Systems Market is projected to reach USD 8,794.97 million by 2027 from USD 4,432.35 million in 2021, at a CAGR 12.09% during the forecast period.

In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

The report on continuous glucose monitoring systems identifies key attributes about the customer to define the potential market and identify different needs across the industry.

Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. This market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience.

This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan.

Key Findings

• The Americas Continuous Glucose Monitoring Systems Market size was estimated at USD 1,335.31 million in 2021, is expected to reach USD 1,480.39 million in 2022, and is projected to grow at a CAGR of 11.78% to reach USD 2,605.00 million by 2027.
• The Asia-Pacific Continuous Glucose Monitoring Systems Market size was estimated at USD 1,514.93 million in 2021, is expected to reach USD 1,706.40 million in 2022, and is projected to grow at a CAGR of 12.36% to reach USD 3,049.30 million by 2027.
• The Europe, Middle East & Africa Continuous Glucose Monitoring Systems Market size was estimated at USD 1,582.10 million in 2021, is expected to reach USD 1,769.51 million in 2022, and is projected to grow at a CAGR of 12.10% to reach USD 3,140.66 million by 2027.

Company Usability Profiles:

• A. Menarini Diagnostics s.r.l
• Abbott Laboratories
• AgaMatrix Inc.
• Ascensia Diabetes Care Holdings AG
• Dexcom, Inc.
• F. Hoffmann-La Roche Ltd.
• GlySens Incorporated
• Insulet Corporation
• Johnson & Johnson Services, Inc.
• Medtronic PLC
• Medtrum Technologies Inc.
• Nemaura Medical Inc.
• Novo Nordisk A/S
• NXP Semiconductors N.V.
• Senseonics Holdings Inc.
• STMicroelectronics
• Tandem Diabetes Care, Inc.
• Texas Instruments Incorporated
• ViCentra B.V.

Market Segmentation & Coverage:

Component:

• Integrated Insulin Pumps
• Sensors
• Transmitters & Receivers

Demographics:

• Adult Population
• Children Population

Patient Type:

• Type 1 Diabetes
• Type 2 Diabetes

End User:

• Diagnostic Centers & Clinics
• Home Healthcare
• ICUs

Distribution Channel:

• Institutional Sales
• Retail Sales

Region:

• Americas
  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
    • California
    • Delaware
    • Georgia
    • Illinois
    • Minnesota
    • New Hampshire
    • Pennsylvania
    • Tennessee
    • Vermont
    • Washington
• Asia-Pacific
  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
• Europe, Middle East & Africa
  • Algeria
  • France
  • Germany
  • Italy
  • Kenya
  • Netherlands
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Tanzania
  • United Arab Emirates
  • United Kingdom

For more information about this report visit https://www.researchandmarkets.com/r/hdf057

View source version on businesswire.com: https://www.businesswire.com/news/home/20220822005521/en/